CROMOPTIC

Post-LOE

cromolyn sodium

Pfizer

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Apr 1999

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CROMOPTIC (cromolyn sodium) by Pfizer is clinical pharmacology: in vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Approved for the management of patients with mastocytosis. First approved in 1999.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Cromolyn sodium acts by inhibiting the release of histamine and leukotrienes (SRS-A) from the mast cell. Cromolyn sodium has no intrinsic…

Indications (1)

the management of patients with mastocytosis

Worked on CROMOPTIC at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.